Global and China Neoantigen Cancer Vaccine Market Size, Status and Forecast 2021-2027

Publisher Name :
Date: 20-Dec-2021
No. of pages: 105
Inquire Before Buying

Global Neoantigen Cancer Vaccine Scope and Market Size

Neoantigen Cancer Vaccine market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neoantigen Cancer Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type

- Personalized Vaccine

- Off-the-shelf Neovaccines

Segment by Application

- Hospital

- Clinic

- Others

By Region

- North America

- - U.S.

- - Canada

- Europe

- - Germany

- - France

- - U.K.

- - Italy

- - Russia

- - Nordic

- - Rest of Europe

- Asia-Pacific

- - China

- - Japan

- - South Korea

- - Southeast Asia

- - India

- - Australia

- - Rest of Asia

- Latin America

- - Mexico

- - Brazil

- - Rest of Latin America

- Middle East & Africa

- - Turkey

- - Saudi Arabia

- - UAE

- - Rest of MEA

By Company

- Roche

- Medimmune

- Merck

- Advaxis

- Agenus

- Genocea

- Gritstone Oncology

- Neon Therapeutics

- Nouscom

- OSE Immunotherapeutics

- Medigene

- Vaccibody

- Brightpath Biotherapeutics

- Geneos Therapeutics

Global and China Neoantigen Cancer Vaccine Market Size, Status and Forecast 2021-2027

Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Personalized Vaccine
1.2.3 Off-the-shelf Neovaccines
1.3 Market by Application
1.3.1 Global Neoantigen Cancer Vaccine Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neoantigen Cancer Vaccine Market Perspective (2016-2027)
2.2 Neoantigen Cancer Vaccine Growth Trends by Regions
2.2.1 Neoantigen Cancer Vaccine Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neoantigen Cancer Vaccine Historic Market Share by Regions (2016-2021)
2.2.3 Neoantigen Cancer Vaccine Forecasted Market Size by Regions (2022-2027)
2.3 Neoantigen Cancer Vaccine Industry Dynamic
2.3.1 Neoantigen Cancer Vaccine Market Trends
2.3.2 Neoantigen Cancer Vaccine Market Drivers
2.3.3 Neoantigen Cancer Vaccine Market Challenges
2.3.4 Neoantigen Cancer Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neoantigen Cancer Vaccine Players by Revenue
3.1.1 Global Top Neoantigen Cancer Vaccine Players by Revenue (2016-2021)
3.1.2 Global Neoantigen Cancer Vaccine Revenue Market Share by Players (2016-2021)
3.2 Global Neoantigen Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neoantigen Cancer Vaccine Revenue
3.4 Global Neoantigen Cancer Vaccine Market Concentration Ratio
3.4.1 Global Neoantigen Cancer Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neoantigen Cancer Vaccine Revenue in 2020
3.5 Neoantigen Cancer Vaccine Key Players Head office and Area Served
3.6 Key Players Neoantigen Cancer Vaccine Product Solution and Service
3.7 Date of Enter into Neoantigen Cancer Vaccine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neoantigen Cancer Vaccine Breakdown Data by Type
4.1 Global Neoantigen Cancer Vaccine Historic Market Size by Type (2016-2021)
4.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2022-2027)
5 Neoantigen Cancer Vaccine Breakdown Data by Application
5.1 Global Neoantigen Cancer Vaccine Historic Market Size by Application (2016-2021)
5.2 Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neoantigen Cancer Vaccine Market Size (2016-2027)
6.2 North America Neoantigen Cancer Vaccine Market Size by Type
6.2.1 North America Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
6.2.2 North America Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
6.2.3 North America Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
6.3 North America Neoantigen Cancer Vaccine Market Size by Application
6.3.1 North America Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
6.3.2 North America Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
6.3.3 North America Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
6.4 North America Neoantigen Cancer Vaccine Market Size by Country
6.4.1 North America Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
6.4.2 North America Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neoantigen Cancer Vaccine Market Size (2016-2027)
7.2 Europe Neoantigen Cancer Vaccine Market Size by Type
7.2.1 Europe Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
7.2.2 Europe Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
7.2.3 Europe Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
7.3 Europe Neoantigen Cancer Vaccine Market Size by Application
7.3.1 Europe Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
7.3.2 Europe Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
7.3.3 Europe Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
7.4 Europe Neoantigen Cancer Vaccine Market Size by Country
7.4.1 Europe Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
7.4.2 Europe Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size (2016-2027)
8.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type
8.2.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
8.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application
8.3.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
8.4 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region
8.4.1 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neoantigen Cancer Vaccine Market Size (2016-2027)
9.2 Latin America Neoantigen Cancer Vaccine Market Size by Type
9.2.1 Latin America Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
9.2.2 Latin America Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
9.2.3 Latin America Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
9.3 Latin America Neoantigen Cancer Vaccine Market Size by Application
9.3.1 Latin America Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
9.3.2 Latin America Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
9.3.3 Latin America Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
9.4 Latin America Neoantigen Cancer Vaccine Market Size by Country
9.4.1 Latin America Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
9.4.2 Latin America Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size (2016-2027)
10.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type
10.2.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2016-2027)
10.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application
10.3.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2016-2027)
10.4 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country
10.4.1 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Details
11.1.2 Roche Business Overview
11.1.3 Roche Neoantigen Cancer Vaccine Introduction
11.1.4 Roche Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.1.5 Roche Recent Development
11.2 Medimmune
11.2.1 Medimmune Company Details
11.2.2 Medimmune Business Overview
11.2.3 Medimmune Neoantigen Cancer Vaccine Introduction
11.2.4 Medimmune Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.2.5 Medimmune Recent Development
11.3 Merck
11.3.1 Merck Company Details
11.3.2 Merck Business Overview
11.3.3 Merck Neoantigen Cancer Vaccine Introduction
11.3.4 Merck Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.3.5 Merck Recent Development
11.4 Advaxis
11.4.1 Advaxis Company Details
11.4.2 Advaxis Business Overview
11.4.3 Advaxis Neoantigen Cancer Vaccine Introduction
11.4.4 Advaxis Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.4.5 Advaxis Recent Development
11.5 Agenus
11.5.1 Agenus Company Details
11.5.2 Agenus Business Overview
11.5.3 Agenus Neoantigen Cancer Vaccine Introduction
11.5.4 Agenus Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.5.5 Agenus Recent Development
11.6 Genocea
11.6.1 Genocea Company Details
11.6.2 Genocea Business Overview
11.6.3 Genocea Neoantigen Cancer Vaccine Introduction
11.6.4 Genocea Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.6.5 Genocea Recent Development
11.7 Gritstone Oncology
11.7.1 Gritstone Oncology Company Details
11.7.2 Gritstone Oncology Business Overview
11.7.3 Gritstone Oncology Neoantigen Cancer Vaccine Introduction
11.7.4 Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.7.5 Gritstone Oncology Recent Development
11.8 Neon Therapeutics
11.8.1 Neon Therapeutics Company Details
11.8.2 Neon Therapeutics Business Overview
11.8.3 Neon Therapeutics Neoantigen Cancer Vaccine Introduction
11.8.4 Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.8.5 Neon Therapeutics Recent Development
11.9 Nouscom
11.9.1 Nouscom Company Details
11.9.2 Nouscom Business Overview
11.9.3 Nouscom Neoantigen Cancer Vaccine Introduction
11.9.4 Nouscom Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.9.5 Nouscom Recent Development
11.10 OSE Immunotherapeutics
11.10.1 OSE Immunotherapeutics Company Details
11.10.2 OSE Immunotherapeutics Business Overview
11.10.3 OSE Immunotherapeutics Neoantigen Cancer Vaccine Introduction
11.10.4 OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.10.5 OSE Immunotherapeutics Recent Development
11.11 Medigene
11.11.1 Medigene Company Details
11.11.2 Medigene Business Overview
11.11.3 Medigene Neoantigen Cancer Vaccine Introduction
11.11.4 Medigene Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.11.5 Medigene Recent Development
11.12 Vaccibody
11.12.1 Vaccibody Company Details
11.12.2 Vaccibody Business Overview
11.12.3 Vaccibody Neoantigen Cancer Vaccine Introduction
11.12.4 Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.12.5 Vaccibody Recent Development
11.13 Brightpath Biotherapeutics
11.13.1 Brightpath Biotherapeutics Company Details
11.13.2 Brightpath Biotherapeutics Business Overview
11.13.3 Brightpath Biotherapeutics Neoantigen Cancer Vaccine Introduction
11.13.4 Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.13.5 Brightpath Biotherapeutics Recent Development
11.14 Geneos Therapeutics
11.14.1 Geneos Therapeutics Company Details
11.14.2 Geneos Therapeutics Business Overview
11.14.3 Geneos Therapeutics Neoantigen Cancer Vaccine Introduction
11.14.4 Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021)
11.14.5 Geneos Therapeutics Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Neoantigen Cancer Vaccine Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Personalized Vaccine
Table 3. Key Players of Off-the-shelf Neovaccines
Table 4. Global Neoantigen Cancer Vaccine Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 5. Global Neoantigen Cancer Vaccine Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 6. Global Neoantigen Cancer Vaccine Market Size by Regions (2016-2021) & (US$ Million)
Table 7. Global Neoantigen Cancer Vaccine Market Share by Regions (2016-2021)
Table 8. Global Neoantigen Cancer Vaccine Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 9. Global Neoantigen Cancer Vaccine Market Share by Regions (2022-2027)
Table 10. Neoantigen Cancer Vaccine Market Trends
Table 11. Neoantigen Cancer Vaccine Market Drivers
Table 12. Neoantigen Cancer Vaccine Market Challenges
Table 13. Neoantigen Cancer Vaccine Market Restraints
Table 14. Global Neoantigen Cancer Vaccine Revenue by Players (2016-2021) & (US$ Million)
Table 15. Global Neoantigen Cancer Vaccine Market Share by Players (2016-2021)
Table 16. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neoantigen Cancer Vaccine as of 2020)
Table 17. Ranking of Global Top Neoantigen Cancer Vaccine Companies by Revenue (US$ Million) in 2020
Table 18. Global 5 Largest Players Market Share by Neoantigen Cancer Vaccine Revenue (CR5 and HHI) & (2016-2021)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Neoantigen Cancer Vaccine Product Solution and Service
Table 21. Date of Enter into Neoantigen Cancer Vaccine Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 24. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2016-2021)
Table 25. Global Neoantigen Cancer Vaccine Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 26. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 27. Global Neoantigen Cancer Vaccine Market Size Share by Application (2016-2021) & (US$ Million)
Table 28. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2016-2021)
Table 29. Global Neoantigen Cancer Vaccine Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 30. Global Neoantigen Cancer Vaccine Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 31. North America Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 32. North America Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 33. North America Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 34. North America Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 35. North America Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 36. North America Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 37. Europe Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 38. Europe Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 39. Europe Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 40. Europe Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 41. Europe Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 42. Europe Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 43. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 44. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 46. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2016-2021) & (US$ Million)
Table 48. Asia-Pacific Neoantigen Cancer Vaccine Market Size by Region (2022-2027) & (US$ Million)
Table 49. Latin America Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 50. Latin America Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 51. Latin America Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 52. Latin America Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 53. Latin America Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 54. Latin America Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 55. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2016-2021) (US$ Million)
Table 56. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Type (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2016-2021) (US$ Million)
Table 58. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Application (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2016-2021) & (US$ Million)
Table 60. Middle East & Africa Neoantigen Cancer Vaccine Market Size by Country (2022-2027) & (US$ Million)
Table 61. Roche Company Details
Table 62. Roche Business Overview
Table 63. Roche Neoantigen Cancer Vaccine Product
Table 64. Roche Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 65. Roche Recent Development
Table 66. Medimmune Company Details
Table 67. Medimmune Business Overview
Table 68. Medimmune Neoantigen Cancer Vaccine Product
Table 69. Medimmune Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 70. Medimmune Recent Development
Table 71. Merck Company Details
Table 72. Merck Business Overview
Table 73. Merck Neoantigen Cancer Vaccine Product
Table 74. Merck Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 75. Merck Recent Development
Table 76. Advaxis Company Details
Table 77. Advaxis Business Overview
Table 78. Advaxis Neoantigen Cancer Vaccine Product
Table 79. Advaxis Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 80. Advaxis Recent Development
Table 81. Agenus Company Details
Table 82. Agenus Business Overview
Table 83. Agenus Neoantigen Cancer Vaccine Product
Table 84. Agenus Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 85. Agenus Recent Development
Table 86. Genocea Company Details
Table 87. Genocea Business Overview
Table 88. Genocea Neoantigen Cancer Vaccine Product
Table 89. Genocea Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 90. Genocea Recent Development
Table 91. Gritstone Oncology Company Details
Table 92. Gritstone Oncology Business Overview
Table 93. Gritstone Oncology Neoantigen Cancer Vaccine Product
Table 94. Gritstone Oncology Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 95. Gritstone Oncology Recent Development
Table 96. Neon Therapeutics Company Details
Table 97. Neon Therapeutics Business Overview
Table 98. Neon Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 99. Neon Therapeutics Recent Development
Table 100. Nouscom Company Details
Table 101. Nouscom Business Overview
Table 102. Nouscom Neoantigen Cancer Vaccine Product
Table 103. Nouscom Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 104. Nouscom Recent Development
Table 105. OSE Immunotherapeutics Company Details
Table 106. OSE Immunotherapeutics Business Overview
Table 107. OSE Immunotherapeutics Neoantigen Cancer Vaccine Product
Table 108. OSE Immunotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 109. OSE Immunotherapeutics Recent Development
Table 110. Medigene Company Details
Table 111. Medigene Business Overview
Table 112. Medigene Neoantigen Cancer Vaccine Product
Table 113. Medigene Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 114. Medigene Recent Development
Table 115. Vaccibody Company Details
Table 116. Vaccibody Business Overview
Table 117. Vaccibody Neoantigen Cancer Vaccine Product
Table 118. Vaccibody Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 119. Vaccibody Recent Development
Table 120. Brightpath Biotherapeutics Company Details
Table 121. Brightpath Biotherapeutics Business Overview
Table 122. Brightpath Biotherapeutics Neoantigen Cancer Vaccine Product
Table 123. Brightpath Biotherapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 124. Brightpath Biotherapeutics Recent Development
Table 125. Geneos Therapeutics Company Details
Table 126. Geneos Therapeutics Business Overview
Table 127. Geneos Therapeutics Neoantigen Cancer Vaccine Product
Table 128. Geneos Therapeutics Revenue in Neoantigen Cancer Vaccine Business (2016-2021) & (US$ Million)
Table 129. Geneos Therapeutics Recent Development
Table 130. Research Programs/Design for This Report
Table 131. Key Data Information from Secondary Sources
Table 132. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neoantigen Cancer Vaccine Market Share by Type: 2020 VS 2027
Figure 2. Personalized Vaccine Features
Figure 3. Off-the-shelf Neovaccines Features
Figure 4. Global Neoantigen Cancer Vaccine Market Share by Application: 2020 VS 2027
Figure 5. Hospital Case Studies
Figure 6. Clinic Case Studies
Figure 7. Others Case Studies
Figure 8. Neoantigen Cancer Vaccine Report Years Considered
Figure 9. Global Neoantigen Cancer Vaccine Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 10. Global Neoantigen Cancer Vaccine Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Neoantigen Cancer Vaccine Market Share by Regions: 2020 VS 2027
Figure 12. Global Neoantigen Cancer Vaccine Market Share by Regions (2022-2027)
Figure 13. Global Neoantigen Cancer Vaccine Market Share by Players in 2020
Figure 14. Global Top Neoantigen Cancer Vaccine Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neoantigen Cancer Vaccine as of 2020
Figure 15. The Top 10 and 5 Players Market Share by Neoantigen Cancer Vaccine Revenue in 2020
Figure 16. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2016-2021)
Figure 17. Global Neoantigen Cancer Vaccine Revenue Market Share by Type (2022-2027)
Figure 18. North America Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 19. North America Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 20. North America Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 21. North America Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
Figure 22. United States Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 23. Canada Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. Europe Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Europe Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 26. Europe Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 27. Europe Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
Figure 28. Germany Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. France Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. U.K. Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. Italy Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. Russia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Nordic Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Asia-Pacific Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 36. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 37. Asia-Pacific Neoantigen Cancer Vaccine Market Share by Region (2016-2027)
Figure 38. China Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Japan Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. South Korea Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Southeast Asia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. India Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Australia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Latin America Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Latin America Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 46. Latin America Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 47. Latin America Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
Figure 48. Mexico Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Brazil Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Middle East & Africa Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Type (2016-2027)
Figure 52. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Application (2016-2027)
Figure 53. Middle East & Africa Neoantigen Cancer Vaccine Market Share by Country (2016-2027)
Figure 54. Turkey Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Saudi Arabia Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. UAE Neoantigen Cancer Vaccine Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Roche Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 58. Medimmune Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 59. Merck Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 60. Advaxis Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 61. Agenus Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 62. Genocea Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 63. Gritstone Oncology Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 64. Neon Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 65. Nouscom Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 66. OSE Immunotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 67. Medigene Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 68. Vaccibody Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 69. Brightpath Biotherapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 70. Geneos Therapeutics Revenue Growth Rate in Neoantigen Cancer Vaccine Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed
  • Global Nuclear Medicine Cyclotron Systems Market Report, History and Forecast 2018-2029
    Published: 11-Jan-2024        Price: US 3350 Onwards        Pages: 118
    The global Nuclear Medicine Cyclotron Systems market was valued at US$ 220.85 million in 2022 and will reach US$ 283.75 million by the end of 2029, growing at a CAGR of 4.38% during 2023-2029. Asia-Pacific market for Nuclear Medicine Cyclotron Systems was valued at $ 61.16 million in 2022 and will reach $ 104.22 million by 2029, at a CAGR of 5.84% during the forecast period of 2023 through 2029. Report Scope This report aims to provide a comprehensive presentation of the glo......
  • Global Non-imaging Diagnostic Catheter Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 95
    The global Non-imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estim......
  • Global Imaging Diagnostic Catheter Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 90
    The global Imaging Diagnostic Catheter market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during The next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, The chemical drug market is estimated......
  • Global PCR Equipment Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 77
    The global PCR Equipment market was valued at US$ 806 million in 2023 and is anticipated to reach US$ 1230.7 million by 2030, witnessing a CAGR of 6.7% during The forecast period 2024-2030. PCR (Polymerase Chain Reaction) equipment is widely used in molecular biology and genetics research for amplifying DNA and RNA sequences. The market for PCR equipment is influenced by several key drivers. Here are some of The significant market drivers: Advancements in Research and Diagnost......
  • Global Disposable Sterile Syringes and Needles Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 109
    The global Disposable Sterile Syringes and Needles market was valued at US$ 404.4 million in 2023 and is anticipated to reach US$ 539.1 million by 2030, witnessing a CAGR of 2.1% during The forecast period 2024-2030. North American market for Disposable Sterile Syringes and Needles is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Disposable Sterile Syringes and N......
  • Global Orthopaedic Power Tools Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 106
    The global Orthopaedic Power Tools market was valued at US$ 463.3 million in 2023 and is anticipated to reach US$ 746.5 million by 2030, witnessing a CAGR of 7.3% during The forecast period 2024-2030. North American market for Orthopaedic Power Tools is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Orthopaedic Power Tools is estimated to increase from $ million i......
  • Global Cerebrospinal Fluid Management Devices Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 86
    The global Cerebrospinal Fluid Management Devices market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Cerebrospinal Fluid Management Devices is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Cerebrospinal Fluid Management Devices is estimate......
  • Global CAD & CAM Milling Burs Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 79
    The global CAD & CAM Milling Burs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for CAD & CAM Milling Burs is estimated to increase from $ million in 2023 to reach $ ......
  • Global Artificial Teeth Market Research Report 2024
    Published: 10-Jan-2024        Price: US 2900 Onwards        Pages: 98
    The global Artificial Teeth market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during The forecast period 2024-2030. North American market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during The forecast period of 2024 through 2030. Asia-Pacific market for Artificial Teeth is estimated to increase from $ million in 2023 to reach $ million by 2030, a......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs